At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INTS Intensity Therapeutics, Inc.
Market Closed 03-21 16:00:00 EDT
2.00
+0.07
+3.63%
盘后1.92
-0.08-4.00%
17:40 EDT
High2.12Low1.94Vol43.22K
Open1.98D1 Closing1.93Amplitude9.33%
Mkt Cap30.21MTradable Cap11.08MTotal Shares15.10M
T/O87.31KT/O Rate0.78%Tradable Shares5.54M
P/B10.35ROE-202.34%EPS-1.17
52wk High5.6952wk Low1.50P/E-1.71
Dividend0.00Div.Yield0.00ROA-93.90%
Loading ...
Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Dow Jones  ·  03-13
Press Release: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("Invincible-3 Study") Following Periodic Review
THOMSON REUTERS  ·  01-28
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("Invincible-3 Study") Following Periodic Review
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR Newswire  ·  01-28
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5
THOMSON REUTERS  ·  01-13
Intensity Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $8.5
Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6
THOMSON REUTERS  ·  01-10
Intensity Therapeutics Provides Business Update Highlighting Key Achievements With Lead Drug Candidate Int230-6
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
PR Newswire  ·  01-10
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares
MT Newswires Live  ·  2024-12-13
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
MT Newswires Live  ·  2024-12-12
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
TIPRANKS  ·  2024-12-12
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
PR Newswire  ·  2024-12-12
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.
TIPRANKS  ·  2024-11-21
Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.
BRIEF-Intensity Therapeutics Announces Pricing Of $3 Million Registered Direct Offering And Concurrent Private Placement
Reuters  ·  2024-11-21
BRIEF-Intensity Therapeutics Announces Pricing Of $3 Million Registered Direct Offering And Concurrent Private Placement
Intensity Therapeutics Inc - to Issue 1,237,113 Shares at $2.425 per Share
THOMSON REUTERS  ·  2024-11-21
Intensity Therapeutics Inc - to Issue 1,237,113 Shares at $2.425 per Share
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
THOMSON REUTERS  ·  2024-11-21
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Press Release: Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Dow Jones  ·  2024-11-21
Press Release: Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma
TIPRANKS  ·  2024-11-18
Intensity Therapeutics presents INT230-6 Phase 1/2 daya in Sarcoma
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
PR Newswire  ·  2024-11-18
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
THOMSON REUTERS  ·  2024-11-13
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2024-11-11
Calendar of U.S. Earnings Expected in the Week Ahead
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
PR Newswire  ·  2024-11-08
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Introduction

Company Name.
Intensity Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App